Larotrectinib sulphate

Grey

Brand Name(s):Vitrakvi

Indication:Solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion

Rationale:1

Considered:Oct-19

Review Date:Aug-25

Comments:
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours (May 2020)